Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eli lilly

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,061 result(s) found for: eli lilly. Displaying page 5 of 54.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-000892-28 Sponsor Protocol Number: I1F-MC-RHBS Start Date*: 2015-08-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I1F-MC-RHBS A 52-Week Multicenter, Randomized, Blinded, Parallel Group Study Comparing the Efficacy and Safety of Ixekizumab to Ustekinumab in Patients with Moderate to Severe Plaque Psor...
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) HU (Completed) NL (Completed) ES (Completed) AT (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002433-22 Sponsor Protocol Number: I1F-MC-RHBF Start Date*: 2015-11-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter Study with a 36-Week Open-Label Period Followed by a Randomized Double-Blind Withdrawal Period from Week 36 to Week 104 to Evaluate the Long Term Efficacy and Safety of Ixeki...
    Medical condition: Arthritic Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) CZ (Completed) GB (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000873-35 Sponsor Protocol Number: I4V-MC-JAHN Start Date*: 2017-10-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) HU (Completed) AT (Completed) ES (Ongoing) PL (Completed) FR (Completed) DK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002095-24 Sponsor Protocol Number: H9X-MC-GBGE(b) Start Date*: 2015-11-16
    Sponsor Name:Eli LIlly and Company
    Full Title: Protocol H9X-MC-GBGE(b) A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus (AWARD-10: As...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.0 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000426-29 Sponsor Protocol Number: I1Q-MC-JDDE Start Date*: 2011-09-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Undergoing Elective Total Hip Arthroplasty (eTHA)
    Medical condition: Disuse atrophy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004859 10013521 Disuse muscle atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) EE (Completed) ES (Completed) SE (Completed) AT (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002371-18 Sponsor Protocol Number: I8B-MC-ITSB Start Date*: 2019-03-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog with an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents with Type 1 Diabetes PRONTO-PEDS
    Medical condition: Diabetes Mellitus, Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed) CZ (Completed) DE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) AT (Completed) ES (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001978-28 Sponsor Protocol Number: J2G-MC-JZJB Start Date*: 2020-01-08
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naïve, RET-M...
    Medical condition: Male or female patients with progressive, advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) NL (Ongoing) GR (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2012-003941-13 Sponsor Protocol Number: I2R-MC-BIAK Start Date*: 2013-03-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Comparison of LY2605541 versus Human Insulin NPH as Basal Insulin Treatment in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with 2 or more Oral Antihyperglycemic...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10049746 Insulin-requiring type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) ES (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-004574-34 Sponsor Protocol Number: I4V-MC-JAIN Start Date*: 2018-04-05
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moder...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) FR (Completed) AT (Completed) BE (Completed) PL (Completed) FI (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004351-23 Sponsor Protocol Number: I5Q-MC-CGAS Start Date*: 2021-02-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD-1 Study
    Medical condition: Episodic Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Completed) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-010902-13 Sponsor Protocol Number: F1J-MC-HMGF(a) Start Date*: 2010-08-03
    Sponsor Name:LILLY S.A.
    Full Title: Duloxetina versus placebo en el tratamiento de pacientes de avanzada edad con trastorno de ansiedad generalizada Duloxetine versus Placebo in the Treatment of Elderly Patients with Generalized Anx...
    Medical condition: Trastorno de ansiedad generalizada Generalized anxiety disorder (GAD)
    Disease: Version SOC Term Classification Code Term Level
    11 10018105 Trastorno de ansiedad generalizada LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002687-27 Sponsor Protocol Number: I6T-MC-AMAX Start Date*: 2020-04-28
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn's Disease
    Medical condition: Crohn´s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) SK (Trial now transitioned) LV (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) LT (Trial now transitioned) IT (Trial now transitioned) DK (Prematurely Ended) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001883-21 Sponsor Protocol Number: I5Q-MC-CGAI Start Date*: 2016-01-18
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Chronic Migraine - the REGAIN Study
    Medical condition: Chronic Migraine Headache
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000190-12 Sponsor Protocol Number: I1F-MC-RHBP Start Date*: 2015-07-09
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis
    Medical condition: Moderate to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2015-003932-11 Sponsor Protocol Number: I1F-MC-RHBV Start Date*: 2016-04-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16 Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients with ...
    Medical condition: Radiographic Axial Spondyloarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10041672 Spondylitis ankylosing LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) NL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004699-31 Sponsor Protocol Number: I3O-MC-JSBF Start Date*: 2016-03-23
    Sponsor Name:Eli Lilly and Company
    Full Title: Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo plus Gemcitabine and Cisplatin as First-Line Treatment in Patients with Advanced or Metastatic Biliary Tract Cancer
    Medical condition: Advanced or Metastatic Biliary Tract Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019815 Hepatobiliary neoplasms malignant and unspecified HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) AT (Completed) CZ (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-000600-42 Sponsor Protocol Number: I5Q-MC-CGAW Start Date*: 2018-06-26
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults with Treatment-Resistant Migraine - The CONQUER Study
    Medical condition: Treatment-resistant Migraine
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10027602 Migraine headache LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) CZ (Completed) BE (Completed) NL (Completed) HU (Completed) DK (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002041-31 Sponsor Protocol Number: I4X-MC-JFDA Start Date*: 2016-09-19
    Sponsor Name:Eli Lilly and Company
    Full Title: A Single-Arm, Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Patients with Locally Advanced or Metastatic Squamous Non-Small Cell...
    Medical condition: Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000134-30 Sponsor Protocol Number: I5B-MC-JGDJ Start Date*: 2015-09-22
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin plus Olaratumab versus Doxorubicin plus Placebo in Patients with Advanced or Metastatic Soft Tissue Sarcoma
    Medical condition: Advanced or Metastatic Soft Tissue Sarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10041298 Soft tissue sarcomas histology unspecified HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) HU (Completed) DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) SE (Ongoing) FI (Completed) BE (Completed) NL (Ongoing) PL (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005024-10 Sponsor Protocol Number: I6F-MC-JJCB Start Date*: 2015-07-29
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 1b/Randomized Phase 2 Study to Evaluate LY3039478 in Combination with Dexamethasone in T-ALL/T-LBL Patients
    Medical condition: T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL)
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Apr 22 17:19:35 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA